The Washington Post Closes a Window on Hackers and Big Government
The Washington Post is pushing back against government surveillance, hackers and other nosy folks trying to get a peek at you and your data.
Starting Tuesday it will begin to encrypt parts of its website to make it more difficult to track the reading habits of visitors. The encryption will apply to the Post’s homepage, stories on the site’s national security page and The Switch, its technology policy blog.
A display icon of a small lock in the web address bar will signal readers that pages are encrypted. In addition, the secure pages will start with the letters “https,” rather than the standard “http.”
The encryption also has the potential to make it tougher for governments to censor content. If censors are monitoring website traffic, they can see only the domain a person is visiting, not the specific page. A country would have to block the entire website if it wanted to block content.
The Post acknowledges that the additional security measures could make online advertising less attractive to companies. Advertisers might also be driven away by having to make sure their content is also secure, an extra step some companies might not be willing to take.
The Post is the first major news organization to introduce such security measures. Last fall, The New York Times published a blog post imploring websites to implement secure connections, but it has yet to follow through on its own challenge.
However, other smaller news sources, such as the Intercept and TechDirt, use https technology by default.
Encrypted traffic is becoming increasingly common for many sites, including online banking and web-based email services. Earlier this month, the Obama administration ordered all public federal websites to begin using https technology by the end of 2016.
The social media giant Facebook announced in early June that users could encrypt notifications sent from the website to a user’s personal email address, protecting potentially sensitive emails. Facebook – as well as hackers, spies and others -- will be denied access to the user’s private encryption key.
This move prevents hackers who have accessed a user’s email inbox from being able to understand emails from Facebook without knowing their private key. While a user’s activity on the actual site will not be encrypted, this announcement could be the first in a series of moves to protect Facebooks’ user privacy.
Apple and Google have also implemented more security measures for user privacy over the last year.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.